| Year | Firm | Client | Income | Doc |
|---|---|---|---|---|
| 2024 3rd Quarter - Report |
BAKER & HOSTETLER LLP | FERRING PHARMACEUTICALS, INC. | $60,000 | |
| 2024 2nd Quarter - Report |
BAKER & HOSTETLER LLP | FERRING PHARMACEUTICALS, INC. | $60,000 | |
| 2024 1st Quarter - Termination |
BAKER & HOSTETLER LLP | GAMIDA | $50,000 | |
| 2024 1st Quarter - Report |
BAKER & HOSTETLER LLP | FERRING PHARMACEUTICALS, INC. | $60,000 | |
| 2023 4th Quarter - Report |
BAKER & HOSTETLER LLP | GAMIDA | $50,000 | |
| 2023 4th Quarter - Report |
BAKER & HOSTETLER LLP | FERRING PHARMACEUTICALS, INC. | $60,000 | |
| 2023 3rd Quarter - Report |
BAKER & HOSTETLER LLP | GAMIDA | $50,000 | |
| 2023 3rd Quarter - Report |
BAKER & HOSTETLER LLP | FERRING PHARMACEUTICALS, INC. | $60,000 | |
| 2023 Registration |
BAKER & HOSTETLER LLP | FERRING PHARMACEUTICALS, INC. | — | |
| 2023 2nd Quarter - Report |
BAKER & HOSTETLER LLP | GAMIDA | $50,000 |